FLUNIVAC
InFLUenza virus UNIVersal VACcine development program
| Coordinatore | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 6˙973˙633 € |
| EC contributo | 5˙066˙881 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | coordinator | 1˙218˙786.00 |
| 2 |
ARTEMIS ONE HEALTH RESEARCH BV
Organization address
address: JENALAN 18C contact info |
NL (UTRECHT) | participant | 918˙211.00 |
| 3 |
Q-BIOLOGICALS NV
Organization address
address: TECHNOLOGIEPARK 4 contact info |
BE (GENT) | participant | 606˙002.00 |
| 4 |
PROBIOGEN AG
Organization address
address: Goethestrasse 54 contact info |
DE (Berlin) | participant | 586˙050.00 |
| 5 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 526˙360.00 |
| 6 |
VIB
Organization address
address: Rijvisschestraat 120 contact info |
BE (ZWIJNAARDE - GENT) | participant | 520˙260.00 |
| 7 |
Aimm Therapeutics BV
Organization address
address: Meibergdreef 45 contact info |
NL (Amsterdam) | participant | 394˙662.00 |
| 8 |
NOVAVAX AB
Organization address
address: KUNGSGATAN 109 contact info |
SE (UPPSALA) | participant | 296˙550.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses continue to escape from and evade immunity. Current influenza vaccines fail to provide long-lasting and broad protection against multiple strains of influenza. For the development of a universal influenza vaccine, we have to “do better than Nature”, since even natural influenza virus infections fail to induce broad protective immunity. To induce broad-protective and long-lasting immunity an influenza vaccine should therefore be directed to conserved viral proteins or regions thereof that are insufficiently exposed upon natural infection. FLUNIVAC is a SME-targeted collaborative research project that aims to develop a candidate influenza vaccine based on recombinant MVA expressing both antibody and T-cell response-inducing proteins, ready to commence Phase I clinical trials within 4 years. We will generate recombinant MVAs that express nine conserved (regions of) influenza A virus proteins (surface proteins HA, NA, M2e, internal proteins M1, NP, NS1, and the polymerase proteins PB1, PB2, PA). These proteins are targets for both antibody and T-cell mediated immune responses, since the induction of solely one of both affords only modest protection against infection with influenza viruses of heterologous subtypes. These recombinant MVAs will be tested for their capacity to induce the desired broad-protective immune response individually and in selected combinations in vivo. In parallel, MVA-induced immune responses will be tested for their longevity and boostability as compared with those induced with adjuvanated vaccine preparations. Furthermore, the MVA platform will be optimized in terms of: i) kinetics and extent of protein-expression of the MVA vector to optimally activate the respective arms of the immune system; ii) a viable unified production process, independent of embryonated chicken eggs, will be designed and implemented.